WO2008029152A3 - Treatment of duchenne muscular dystrophy - Google Patents

Treatment of duchenne muscular dystrophy Download PDF

Info

Publication number
WO2008029152A3
WO2008029152A3 PCT/GB2007/003377 GB2007003377W WO2008029152A3 WO 2008029152 A3 WO2008029152 A3 WO 2008029152A3 GB 2007003377 W GB2007003377 W GB 2007003377W WO 2008029152 A3 WO2008029152 A3 WO 2008029152A3
Authority
WO
WIPO (PCT)
Prior art keywords
muscular dystrophy
different
same
duchenne muscular
treatment
Prior art date
Application number
PCT/GB2007/003377
Other languages
French (fr)
Other versions
WO2008029152A2 (en
Inventor
Graham Michael L Wynne
Stephen Paul Wren
Cristina Lecci
Original Assignee
Summit Corp Plc
Graham Michael L Wynne
Stephen Paul Wren
Cristina Lecci
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0617739A external-priority patent/GB0617739D0/en
Priority claimed from GB0619282A external-priority patent/GB0619282D0/en
Priority claimed from GB0623985A external-priority patent/GB0623985D0/en
Application filed by Summit Corp Plc, Graham Michael L Wynne, Stephen Paul Wren, Cristina Lecci filed Critical Summit Corp Plc
Publication of WO2008029152A2 publication Critical patent/WO2008029152A2/en
Publication of WO2008029152A3 publication Critical patent/WO2008029152A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Abstract

There are disclosed compounds of formula I, wherein A1, A2, A3, A4 and A5 which may be the same or different, represent N or CR1 Y and Z, which may be the same or different, represent O, S(O)n, C=W, NR4, NC(=O)R5 and CR6R7, W is O, S, NR20, one of R4, R5, R6, and R20 represents - L - R3, in which L is a single bond or a linker group, additionally, R3, R 4, R 5, R6, and R7, which may be the same or different, independently represent hydrogen or a substituent-or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the therapeutic arid/or prophylactic treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia.
PCT/GB2007/003377 2006-09-08 2007-09-07 Treatment of duchenne muscular dystrophy WO2008029152A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0617739A GB0617739D0 (en) 2006-09-08 2006-09-08 Treatment of duchenne muscular dystrophy
GB0617739.8 2006-09-08
GB0619282.7 2006-09-29
GB0619282A GB0619282D0 (en) 2006-09-29 2006-09-29 Treatment of duchenne muscular dystrophy
GB0623985A GB0623985D0 (en) 2006-11-30 2006-11-30 Treatment of duchenne muscular dystrophy
GB0623985.9 2006-11-30

Publications (2)

Publication Number Publication Date
WO2008029152A2 WO2008029152A2 (en) 2008-03-13
WO2008029152A3 true WO2008029152A3 (en) 2008-05-08

Family

ID=38947387

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/003377 WO2008029152A2 (en) 2006-09-08 2007-09-07 Treatment of duchenne muscular dystrophy

Country Status (1)

Country Link
WO (1) WO2008029152A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
JP2010510987A (en) 2006-11-27 2010-04-08 ハー・ルンドベック・アクチエゼルスカベット Heteroarylamide derivatives
EP1964840A1 (en) * 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]pyridines and their use as pharmaceuticals
GB0715938D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment of duchenne muscular dystrophy
US8067409B2 (en) 2007-11-27 2011-11-29 Abbott Laboratories Protein kinase inhibitors
KR101492308B1 (en) * 2008-05-14 2015-02-11 가부시키가이샤 오츠까 세이야꾸 고죠 Lipoprotein lipase-activating compositions comprising benzene derivates
GB0809314D0 (en) * 2008-05-22 2008-07-02 Summit Corp Plc Compounds for treating muscular dystrophy
RU2518892C2 (en) * 2008-09-23 2014-06-10 Виста Лабораториз Лтд. Ligands for aggregated molecules of tau-protein
TWI491610B (en) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 Imidazopyridazinecarbonitriles useful as kinase inhibitors
GB0822981D0 (en) * 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
WO2010086040A1 (en) * 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
WO2010129620A1 (en) * 2009-05-05 2010-11-11 Alla Chem, Llc Imidazo [ 1, 2 -a] pyridin-2 -yl-phenyl derivatives to be used in cancer treatment
CN102574789B (en) 2009-09-21 2014-12-10 凯莫森特里克斯股份有限公司 Pyrrolidinone carboxamide derivatives as chemerin-R ( CHEMR23 ) modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
SG184987A1 (en) 2010-04-22 2012-11-29 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
TWI617559B (en) * 2010-12-22 2018-03-11 江蘇恆瑞醫藥股份有限公司 2-arylimidazo[1,2-b]pyridazine, 2-phenylimidazo[1,2-a]pyridine, and 2-phenylimidazo[1,2-a]pyrazine derivatives
ES2545135T3 (en) 2011-04-06 2015-09-08 Bayer Pharma Aktiengesellschaft Substituted Imidazopyridines and intermediates thereof
EP2939675B1 (en) * 2012-12-28 2019-09-04 Shin Nippon Biomedical Laboratories, Ltd. Oct3 activity inhibitor containing imidazopyridine derivative as active component, and oct3 detection agent
CN105008366B (en) 2013-03-11 2017-11-14 百时美施贵宝公司 Pyrrolopyridazine class compound as potassium channel inhibitors
PL3925607T3 (en) 2014-04-15 2023-10-30 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
DK3174868T3 (en) 2014-08-01 2021-11-08 Nuevolution As COMPOUNDS ACTIVE AGAINST BROMODOMAINS
TW201643143A (en) * 2015-03-13 2016-12-16 國立大學法人北海道大學 Compound for inhibiting neuronal cell death induced by oxidative stress
WO2021240187A1 (en) * 2020-05-29 2021-12-02 Semmelweis Egyetem Benzamide derivatives as anti-inflammatory compounds and uses thereof
EP4265248A1 (en) * 2022-04-22 2023-10-25 Université Paris Cité Compounds inducing production of proteins by immune cells

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000092A1 (en) * 1989-06-13 1991-01-10 Smithkline Beecham Corporation Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages
WO2004050076A1 (en) * 2002-11-28 2004-06-17 Centre National De La Recherche Scientifique Cnrs Use of a histone deacetylase inhibitor for treating muscular dystrophies
WO2005092899A1 (en) * 2004-03-26 2005-10-06 Methylgene Inc. Inhibitors of histone deacetylase
WO2005105798A1 (en) * 2004-04-30 2005-11-10 Grünenthal GmbH Substituted imidazo[1,2-a]pyridine compounds and drugs containing substituted imidazo[1,2-a]pyridine compounds
US20050288502A1 (en) * 2004-06-25 2005-12-29 Andersen Denise L Substituted heterocyclic compounds and methods of use
WO2006007910A1 (en) * 2004-07-20 2006-01-26 Santhera Pharmaceuticals (Schweiz) Ag Use of non-glucocorticoid steroids for the treatment of muscular dystrophy
WO2006094235A1 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
WO2006094236A1 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. N-phenyl benzamide derivatives as sirtuin modulators
WO2006101455A1 (en) * 2005-03-21 2006-09-28 S*Bio Pte Ltd Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000092A1 (en) * 1989-06-13 1991-01-10 Smithkline Beecham Corporation Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages
WO2004050076A1 (en) * 2002-11-28 2004-06-17 Centre National De La Recherche Scientifique Cnrs Use of a histone deacetylase inhibitor for treating muscular dystrophies
WO2005092899A1 (en) * 2004-03-26 2005-10-06 Methylgene Inc. Inhibitors of histone deacetylase
WO2005105798A1 (en) * 2004-04-30 2005-11-10 Grünenthal GmbH Substituted imidazo[1,2-a]pyridine compounds and drugs containing substituted imidazo[1,2-a]pyridine compounds
US20050288502A1 (en) * 2004-06-25 2005-12-29 Andersen Denise L Substituted heterocyclic compounds and methods of use
WO2006007910A1 (en) * 2004-07-20 2006-01-26 Santhera Pharmaceuticals (Schweiz) Ag Use of non-glucocorticoid steroids for the treatment of muscular dystrophy
WO2006094235A1 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
WO2006094236A1 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. N-phenyl benzamide derivatives as sirtuin modulators
WO2006101455A1 (en) * 2005-03-21 2006-09-28 S*Bio Pte Ltd Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications

Also Published As

Publication number Publication date
WO2008029152A2 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
WO2008029152A3 (en) Treatment of duchenne muscular dystrophy
WO2008029168A3 (en) Treatment of duchenne muscular dystrophy
WO2008142055A3 (en) Antiviral agents
WO2007091106A3 (en) Treatment of duchenne muscular dystrophy
MX2009006742A (en) Novel compounds.
MY145647A (en) (4-hydroxy-2-oxo-3h-benzothiazol-7-yl)ethylamine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy (for example in the treatment of respiratory disease states)
WO2008126034A3 (en) Oxazolidinone antibiotics
MX2009012558A (en) Drug combinations for the treatment of duchenne muscular dystrophy.
MY127126A (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
TW200738242A (en) Dihydropteridinones in the treatment of respiratory diseases
EP2041159B8 (en) Macrocyclic compounds as antiviral agents
MX2009003157A (en) Therapeutic pyrazolyl thienopyridines.
TW200602328A (en) Quinazoline derivatives
TW200621762A (en) Novel compounds
IL182315A0 (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
WO2005111002A3 (en) Substituted cycloalkyl derivatives for use in the treatment of respiratory diseases
MY145133A (en) Aryl-substituted polycyclic amines, process for their preparation and their use as medicaments
GB0413087D0 (en) Therapeutic compounds
WO2008069917A3 (en) Novel cyclic peptides
WO2010066629A3 (en) Novel azaindoles
MX2009008756A (en) Macrocyclic compound.
GEP20135883B (en) Iminopyridine derivatives and usage thereof
WO2005040171A8 (en) Pyrazolo and imidazo-pyrimidine derivatives
TW200716547A (en) Piperidin-4-yl-amide derivatives
MXPA05011472A (en) The use of azetidinecarboxamide derivatives in therapy.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07804177

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07804177

Country of ref document: EP

Kind code of ref document: A2